PBM vs DTC: Will the Middlemen Be Bypassed?

For decades, the United States pharmaceutical system has been characterized by a complex distribution structure involving manufacturers, wholesalers, pharmacies, insurers, and a key intermediary known as the Pharmacy Benefit Manager (PBM). PBMs manage prescription drug benefits for insurers and employers and negotiate prices between drug manufacturers and pharmacies.

In recent years, however, a new distribution model—Direct-to-Consumer (DTC) pharmaceutical platforms—has emerged. Companies such as Eli Lilly, Novo Nordisk, and Pfizer have begun selling medications directly to patients through digital platforms that combine telemedicine, online prescribing, and home delivery.

At first glance, this shift appears disruptive. If pharmaceutical companies can sell medications directly to patients, what role remains for PBMs? Are these long-standing intermediaries becoming obsolete?

The reality is more nuanced. While DTC platforms are reshaping how some drugs reach patients, the broader pharmaceutical ecosystem remains deeply dependent on insurance-based benefit management systems. Rather than replacing PBMs outright, the DTC movement is revealing structural weaknesses in the current model and prompting regulatory reforms aimed at improving transparency.

Understanding this transformation requires examining three key dimensions:

Why PBMs became central to the U.S. healthcare system.

Why pharmaceutical companies are investing in DTC distribution channels.

How regulatory reforms and market dynamics may reshape the balance between the two models in the coming years.

The Rise of PBMs: Managing Complexity in Drug Benefits

Historical Origins

PBMs emerged in the late 1960s, primarily to process prescription drug claims for insurance companies. As employer-sponsored health insurance expanded in the United States, insurers needed systems capable of managing pharmacy networks, verifying prescriptions, and reimbursing pharmacies efficiently.

Over time, PBMs evolved into powerful negotiators within the pharmaceutical supply chain. Today, three companies dominate the market:

CVS Caremark;

Express Scripts (Cigna);

OptumRx (UnitedHealth Group);

Together, these organizations manage roughly 80% of U.S. prescription drug claims, meaning that most insured patients receive medications within frameworks defined by PBM contracts.

Core Functions of PBMs:

PBMs perform several functions that are operationally essential in large insurance systems:

1. Negotiating Drug Prices
PBMs negotiate rebates and discounts with pharmaceutical manufacturers in exchange for preferred placement on formularies (lists of covered medications).

2. Managing Pharmacy Networks
PBMs determine which pharmacies participate in insurance plans and negotiate reimbursement rates.

3. Formulary Design

They create tiers of medications that influence patient copayments and prescribing patterns.

4. Drug Utilization Review

PBMs monitor prescriptions for safety, duplication, and cost-effectiveness.

These services helped insurers manage rising drug costs during the rapid expansion of pharmaceutical innovation in the late 20th century.

The Controversial Rebate Model:

Despite these benefits, the PBM business model has faced increasing criticism.

Many PBMs derive revenue from rebates negotiated with manufacturers, often tied to a drug’s list price rather than its net cost. This system has created a paradox: manufacturers may raise list prices while offering larger rebates to secure favorable formulary placement.

Economic analyses suggest that this “high list price–high rebate” model can distort incentives within the supply chain. Patients whose copayments or deductibles are calculated based on list prices may ultimately pay more, even when insurers receive significant rebates later in the process.

By 2025, several policy analyses indicated that rebate-driven pricing had become a central contributor to public concern over drug affordability in the United States. [1]

The Emergence of Direct-to-Consumer Drug Platforms:

Digital Platforms and the Shift Toward Patient Access

Against this backdrop, pharmaceutical companies began exploring new ways to reach patients directly. Advances in telemedicine, online pharmacy regulation, and logistics have made it technically feasible to connect patients with prescribing physicians and deliver medications to their homes.

Several major pharmaceutical companies have launched DTC initiatives:

Eli Lilly – LillyDirect;

Novo Nordisk – NovoCare Pharmacy;

Pfizer – Pfizer for All;

These platforms typically integrate several services:

Online medical consultations;

Prescription generation by licensed clinicians;

Pharmacy fulfillment and home delivery;

Transparent cash pricing;

This model represents a major shift from traditional distribution channels.

Case Study: LillyDirect

Launched in 2024, LillyDirect initially focused on medications for diabetes, obesity, and migraine. The platform partners with telehealth providers and digital pharmacies to connect patients directly with prescribing physicians and medication delivery services.

Eli Lilly also collaborated with Amazon Pharmacy, leveraging existing e-commerce logistics to streamline delivery. The integration of telemedicine and e-commerce reflects broader trends toward digitally mediated healthcare.

Industry observers note that LillyDirect serves two strategic purposes:

Expanding patient access to high-demand medications.

Allowing the manufacturer greater control over pricing and distribution.

Novo Nordisk’s Self-Pay Pricing Model

Novo Nordisk adopted a similar approach through its NovoCare platform, particularly for GLP-1 medications used in obesity treatment.

As of March 2026, NovoCare offered the weight-loss medication Wegovy (semaglutide) for approximately $499 per month for self-pay patients, with promotional pricing as low as $199 for the first two months for new patients.

These prices remain substantial but represent a significant reduction compared with earlier U.S. list prices that exceeded $1,000 per month.

Such pricing strategies illustrate one of the main advantages of the DTC model: removing several intermediaries allows manufacturers to offer lower direct prices while maintaining margins.

Why DTC Platforms Target Specific Drug Categories?

Despite their visibility, DTC platforms currently focus on a limited set of medications rather than the full pharmaceutical market.

Several categories are particularly suited to the DTC model:

1. High-demand lifestyle or chronic disease drugs

Examples include GLP-1 receptor agonists used for obesity and diabetes.

2. Medications with limited insurance coverage

Weight-loss medications are frequently excluded from employer-sponsored health plans.

3. Drugs with strong consumer awareness

Migraine treatments and COVID-19 antivirals fall into this category.

For patients without insurance coverage, DTC platforms may offer a more predictable and sometimes lower price.

However, this model does not yet address the majority of prescription drugs used for chronic conditions such as hypertension, asthma, or cardiovascular disease, which are typically obtained through insurance plans managed by PBMs.

The Expanding DTC Ecosystem

The DTC movement is no longer limited to a few pharmaceutical companies.

Several manufacturers have introduced direct-purchase programs for specific medications, often with transparent flat pricing:

Examples include:

Amgen – Repatha (cholesterol therapy)

AbbVie – Synthroid Delivers

Bristol Myers Squibb – Patient Connect

AstraZeneca Direct

These programs typically offer self-pay pricing discounts ranging from 40% to 80% compared with U.S. list prices.

In addition, government and industry organizations are exploring broader platforms designed to aggregate these programs. Proposed initiatives such as national drug-pricing transparency portals aim to help patients identify manufacturer-sponsored discount programs and compare prices across therapies.

These developments suggest that DTC distribution is becoming a permanent component of the pharmaceutical market rather than a temporary experiment.

Regulatory Reform: A Turning Point in 2026

The evolving relationship between PBMs and DTC platforms cannot be understood without examining regulatory changes.

PBM Reform in Federal Policy

The 2026 Comprehensive Appropriations Act introduced several reforms aimed at improving transparency in pharmacy benefit management.

Key provisions affecting Medicare Part D include:

1. 100% Rebate Pass-Through
PBMs must pass manufacturer rebates fully to health plans rather than retaining them as profit.

2. Delinking PBM Compensation from Drug Prices
PBMs may only receive fixed service fees rather than payments tied to drug prices or rebates.

3. Detailed Reporting Requirements
PBMs must disclose rebate structures, pharmacy reimbursement rates, and pricing practices to regulators.

These reforms are scheduled to take effect January 1, 2028.

While the provisions initially apply to Medicare, analysts expect similar transparency requirements to influence the commercial insurance market as well.

Federal Trade Commission Oversight

The Federal Trade Commission (FTC) has also begun investigating PBM practices, focusing on:

Rebate structures;

Spread pricing between insurers and pharmacies;

Lack of pricing transparency;

Some settlements have already required PBMs to offer employer health plans the option of calculating patient cost-sharing based on net drug prices rather than list prices.

If widely implemented, such changes could reduce patient out-of-pocket costs and weaken incentives that previously encouraged high list prices.

Employers and the End of the Data “Black Box”

Employers sponsor health insurance for roughly 160 million Americans, making them key stakeholders in the PBM system.

Historically, employers had limited visibility into how PBMs generated revenue. Drug pricing structures—including rebates and pharmacy reimbursement differences—were often treated as proprietary information.

Recent policy changes linked to the Employee Retirement Income Security Act (ERISA) are beginning to change this dynamic. Employers are gaining access to more detailed prescription-drug cost data, including:

Manufacturer rebates;

Pharmacy reimbursement rates;

PBM administrative fees;

Greater transparency may alter how employers negotiate contracts with PBMs and potentially encourage alternative benefit models.

An Unexpected Twist: PBMs Adopting DTC Features

Interestingly, PBMs themselves have begun experimenting with DTC-style pricing models.

Some PBM programs now allow patients to purchase medications at cash prices tied to wholesale acquisition cost (WAC) plus a dispensing fee. These programs are typically available for patients without insurance coverage.

In effect, PBMs are adapting the DTC concept rather than resisting it. This hybrid approach reflects a broader industry trend: instead of eliminating intermediaries, companies are redesigning their roles within the distribution chain.

The Strategic Motives Behind Pharmaceutical DTC Platforms

The rapid expansion of DTC platforms is not driven solely by patient access concerns. Pharmaceutical companies also have strategic motivations.

Control Over Pricing

Direct distribution allows manufacturers to avoid rebate negotiations and set transparent prices.

Data Access

DTC platforms provide companies with direct insights into patient behavior, treatment adherence, and prescribing patterns.

Brand Engagement

Pharmaceutical firms can communicate directly with patients about treatment options, improving awareness and potentially expanding market demand.

Market Expansion

DTC channels can reach patients excluded from insurance coverage or living in areas with limited access to specialists.

These advantages explain why DTC initiatives have expanded beyond a few experimental programs.

The Limits of the DTC Model

Despite its promise, the DTC approach faces several structural limitations.

Insurance Integration

Most Americans obtain medications through insurance plans. DTC platforms that rely on cash payments may not be financially feasible for patients requiring multiple medications.

Fragmented Purchasing

Patients managing several chronic conditions may find it impractical to obtain medications from multiple manufacturer websites.

Regulatory Oversight

DTC platforms must ensure proper prescription verification, privacy protections, and pharmacovigilance systems.

Pharmacy Infrastructure

Traditional pharmacy networks provide services such as medication counseling, vaccination, and monitoring for drug interactions.

These services are difficult to replicate entirely within purely digital distribution models.

Future Market Structure: Coexistence Rather Than Replacement

The current evidence suggests that the pharmaceutical distribution system is evolving toward a multi-channel structure rather than a single dominant model.

Three layers are likely to coexist:

1. PBM-Managed Insurance Systems

These will continue to serve the majority of insured patients.

2. Manufacturer DTC Channels

These platforms will provide alternative access for self-pay patients and high-demand therapies.

3. Hybrid Digital Pharmacy Platforms

Telemedicine providers and online pharmacies will integrate elements of both systems.

Rather than eliminating PBMs, DTC innovation is pushing them to become more transparent and service-oriented.

Looking Ahead: Key Trends to Watch

Several developments may shape the PBM–DTC relationship in the coming years.

1. Implementation of PBM Regulations

As federal reforms take effect between 2027 and 2029, the financial incentives that shaped the rebate-driven system may change significantly.

2. Expansion of DTC Drug Portfolios

More pharmaceutical companies are expected to introduce direct-purchase programs for high-cost medications.

3. Integration with Telemedicine

DTC platforms are increasingly incorporating remote diagnosis services and digital care management.

4. Employer-Sponsored Alternatives

Some employers are exploring direct contracts with manufacturers or pharmacy networks outside traditional PBM arrangements.

These changes suggest that the pharmaceutical market is entering a period of structural experimentation.

Conclusion

The debate over whether PBMs will be bypassed may be asking the wrong question.

PBMs remain deeply embedded in the insurance-based healthcare system, and their operational infrastructure—pharmacy networks, utilization review systems, and benefit management tools—cannot easily be replaced.

However, the rise of DTC platforms has revealed an important shift: patients, employers, and regulators increasingly demand transparent drug pricing.

Both regulatory reforms and direct purchasing models are converging toward the same goal—clarifying how much medications actually cost and who receives the associated revenue.

In this sense, the future of pharmaceutical distribution is less about eliminating intermediaries and more about redefining their roles. The next phase of reform may transform PBMs from rebate-driven negotiators into transparent service providers, while DTC platforms continue expanding as complementary channels for specific therapies.

For patients, the result may be a healthcare system with more choices—but also more complexity in deciding how to access medications.

References:

[1] Dusetzina, S. B., Conti, R. M., Yu, N. L., & Bach, P. B. (2024). Association of pharmacy benefit manager rebates with drug pricing in the United States. JAMA Health Forum, 5(3). https://jamanetwork.com/journals/jama-health-forum

[2] U.S. Federal Trade Commission. (2025). Pharmacy Benefit Managers: The powerful middlemen affecting drug prices. https://www.ftc.gov

[3] U.S. Department of Health and Human Services. (2026). Medicare Part D policy reforms under the Comprehensive Appropriations Act. https://www.hhs.gov

[4] IQVIA Institute for Human Data Science. (2025). The use of medicines in the U.S.: Trends and outlook through 2028. https://www.iqvia.com

[5] U.S. Food and Drug Administration. (2026). Digital health and telemedicine regulatory updates for online pharmacy services. https://www.fda.gov

About the Author:

Dr. Andrew T. Collins is a physician and public health researcher specializing in pharmaceutical policy, healthcare economics, and emerging digital healthcare delivery models. He earned his MD from the University of Pittsburgh School of Medicine and a Master of Public Health from Columbia University’s Mailman School of Public Health. His work focuses on how structural changes in drug distribution—including pharmacy benefit management systems, telehealth platforms, and direct-to-consumer pharmaceutical services—affect medication pricing, patient access, and healthcare system transparency. Dr. Collins writes regularly on healthcare policy trends and the evolving relationship between pharmaceutical innovation, regulation, and public health outcomes.

Disclaimer

This article is intended for educational and informational purposes only. It does not provide medical advice, diagnosis, or treatment recommendations. Readers should consult qualified healthcare professionals for personal medical decisions. Information presented reflects current research, regulatory announcements, and policy discussions available as of 2026.